Blog
RSS FeedPosted by Michael Wonder on 26 Apr 2017
NICE backs NHS use of Lilly’s Taltz for plaque psoriasis
26 April 2017 - US pharma major Eli Lilly says that Taltz (ixekizumab) has been recommended by the NICE for ...
Posted by Michael Wonder on 20 Apr 2017
Ipsen in talks with NICE over Cabometyx rejection
20 April 2017 - Ipsen says discussions with NICE are ongoing following a second rejection of Cabometyx for advanced renal ...
Posted by Michael Wonder on 19 Apr 2017
NICE nod for Novartis’ Cosentyx in psoriatic arthritis
19 April 2017 - NICE has published a positive Final Appraisal Determination which backs NHS use of Novartis’ Cosentyx (secukinumab) ...
Posted by Michael Wonder on 19 Apr 2017
NICE publishes second appraisal consultation document for cabozantinib maleate
19 April 2017 - The Department of Health has asked NICE to produce guidance on the use of cabozantinib in the ...
Posted by Michael Wonder on 12 Apr 2017
NICE publishes draft guidance on the use of Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells)
12 April 2017 - The Department of Health has asked NICE to produce guidance on using ex vivo expanded autologous human ...
Posted by Michael Wonder on 11 Apr 2017
'Gamechanging' cancer drug rejected for use on NHS
11 April 2017 - Nivolumab deemed too expensive for the benefits but cancer specialists urge NHS and manufacturers to reach compromise. ...
Posted by Michael Wonder on 11 Apr 2017
NICE says head and neck cancer drug is not cost effective
11 April 2017 - NICE has published draft guidance saying the cost of using nivolumab to treat head and neck cancer ...
Posted by Michael Wonder on 06 Apr 2017
Pharma warns new NICE rules will delay access to medicines
3 April 2017 - Pharma companies are warning that changes to the way the National Institute for Health & Care ...
Posted by Michael Wonder on 28 Mar 2017
NICE says pancreatic cancer drug is not cost effective for routine NHS use
28 March 2017 - NICE says that a drug for metastatic pancreatic cancer is not beneficial enough to justify its high ...
Posted by Michael Wonder on 22 Mar 2017
Post-menopausal women with a family history of breast cancer should be offered anastrozole, says NICE in updated guidance
22 March 2017 - Post-menopausal women with a family history of breast cancer should be offered anastrozole, NICE has said in ...
Posted by Michael Wonder on 18 Mar 2017
CAR-T drugs worth up to $649K in childhood leukaemia, says U.K. report
17 March 2017 - Health authorities in Britain ran cost-effectiveness numbers on pioneering CAR-T therapies that might be used to ...
Posted by Michael Wonder on 17 Mar 2017
NICE recommends longer-lasting battery technology for implantable heart rhythm devices
17 March 2017 - People with heart failure are set to benefit from longer-lasting battery technology in implantable heart rhythm devices, ...
Posted by Michael Wonder on 17 Mar 2017
NICE publishes draft guidance on the use of daratumumab (Darzalex) on the NHS
17 March 2017 - The Department of Health has asked NICE to produce guidance on the use of daratumumab as monotherapy ...
Posted by Michael Wonder on 16 Mar 2017
NICE gets go-ahead to fast-track more drug approvals
15 March 2017 - Patients will benefit from access to the most cost-effective treatments nearly 5 months faster after changes to ...
Posted by Michael Wonder on 15 Mar 2017
NICE publishes draft guidance on the use of adalimumab and dexamethasone for uveitis
15 March 2017 - The Department of Health has asked NICE to produce guidance on the use of adalimumab and dexamethasone ...